These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 28498514)

  • 21. Secukinumab in the treatment of psoriasis: an update.
    Reszke R; Szepietowski JC
    Immunotherapy; 2017 Mar; 9(3):229-238. PubMed ID: 28162025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
    Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
    Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
    JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
    [No Abstract]   [Full Text] [Related]  

  • 24. Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report.
    Odorici G; Losi A; Ciardo S; Pellacani G; Conti A
    Skin Res Technol; 2018 Feb; 24(1):160-162. PubMed ID: 29067742
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
    Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
    J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical experience with infliximab biosimilar in psoriasis.
    Ricceri F; Pescitelli L; Lazzeri L; Prignano F
    Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of Moderate to Severe Psoriasis With High-Dose (450-mg) Secukinumab: Case Reports of Off-Label Use.
    Beecker J; Joo J
    J Cutan Med Surg; 2018; 22(1):86-88. PubMed ID: 28735569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secukinumab for the treatment of residual psoriasis: a case series.
    Malagoli P
    J Dermatolog Treat; 2018; 29(sup1):12-13. PubMed ID: 30919723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis.
    Morgado-Carrasco D; Riera-Monroig J; Fustà-Novell X; Alsina Gibert M
    Actas Dermosifiliogr (Engl Ed); 2018; 109(6):565-567. PubMed ID: 29169562
    [No Abstract]   [Full Text] [Related]  

  • 31. Erythrodermic psoriasis and secukinumab: Our clinical experience.
    Mateu-Puchades A; Santos-Alarcón S; Martorell-Calatayud A; Pujol-Marco C; Sánchez-Carazo JL
    Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
    [No Abstract]   [Full Text] [Related]  

  • 32. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
    Weng HJ; Wang TS; Tsai TF
    Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical experience with efalizumab in the Hospital of Cruces].
    Martínez de Lagrán Z; González Hermosa MR; Díaz-Pérez JL
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():74-81. PubMed ID: 18341856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depression? It's the Disease NOT the Drug.
    Kircik LH
    J Drugs Dermatol; 2018 Aug; 17(8):s28. PubMed ID: 30124736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
    Talamonti M; Teoli M; Botti E; Spallone G; Chimenti S; Costanzo A
    Dermatology; 2011; 222(3):250-5. PubMed ID: 21494026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study.
    van den Reek JMPA; van Vugt LJ; van Doorn MBA; van der Kraaij GE; de Kort WJA; Lucker GPH; Horvath B; Njoo MD; Bovenschen HJ; Ossenkoppele PM; De Bruin-Weller MS; de Groot M; Mommers R; Prevoo RLMA; van de Kerkhof PCM; Spuls PI; Kievit W; de Jong EMGJ
    Acta Derm Venereol; 2018 Jul; 98(7):648-654. PubMed ID: 29405245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.